Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
IEEE Transactions on Visualization and Computer Graphics|November 1, 2006
Visualizing Internet routing changesMohit Lad, Dan Massey, Lixia Zhang
Chinese Medical Journal|October 12, 2013
Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary diseaseYan Tang, Dan Massey, Nan-shan Zhong
Treatments in Respiratory Medicine|February 24, 2005
Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfactionWolfgang Schürmann, Sören Schmidtmann, Petra Moroni, et al.
International Journal of Chronic Obstructive Pulmonary Disease|November 30, 2007
Diagnosis of airway obstruction in primary care in the UK: the CADRE (COPD and Asthma Diagnostic/management REassessment) programme 1997-2001Mike Pearson, Jon G Ayres, Maria Sarno, et al.
Plos One|February 21, 2020
Characterization of gut microbiomes of household pets in the United States using a direct-to-consumer approachAashish R Jha, Justin Shmalberg, Jirayu Tanprasertsuk, et al.
The Lancet. Neurology|May 11, 2010
Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trialPaolo Barone, Werner Poewe, Stefan Albrecht, et al.
International Journal of Chronic Obstructive Pulmonary Disease|August 18, 2010
Efficacy and safety of tiotropium Respimat SMI in COPD in two 1-year randomized studiesEric Bateman, Dave Singh, David Smith, et al.
Cancer Science|June 23, 2015
Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3Terufumi Kato, Hiroshige Yoshioka, Isamu Okamoto, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 17, 2014
Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancerFederico Cappuzzo, Giovanna Finocchiaro, Francesco Grossi, et al.
The Oncologist|May 29, 2014
Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFRMyung-Ju Ahn, Sang-We Kim, Byoung-Chul Cho, et al.
Pageof 3